Bibliografías temáticas / Mouth Cancer Chemotherapy / Artículos de revistas
Siga este enlace para ver otros tipos de publicaciones sobre el tema: Mouth Cancer Chemotherapy.

Artículos de revistas sobre el tema "Mouth Cancer Chemotherapy"

Autor: Grafiati
Publicado: 4 de junio de 2021
Última modificación: 10 de febrero de 2022

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros

Elija tipo de fuente:

Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Mouth Cancer Chemotherapy".

Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.

También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.

Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.

1

Kalavrezos, Nicholas, and Crispian Scully. "Mouth cancer for clinicians part 12: cancer treatment (chemotherapy and targeted therapy)." Dental Update 43, no. 6 (July 2, 2016): 567–74. http://dx.doi.org/10.12968/denu.2016.43.6.567.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Brown, Carlton G., Susan L. Beck, Douglas E. Peterson, Deborah B. McGuire, William N. Dudley, and Kathleen H. Mooney. "Patterns of sore mouth in outpatients with cancer receiving chemotherapy." Supportive Care in Cancer 17, no. 4 (October 7, 2008): 413–28. http://dx.doi.org/10.1007/s00520-008-0509-y.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Earlam, S., C. Glover, M. Davies, C. Fordy, and T. G. Allen-Mersh. "Effect of regional and systemic fluorinated pyrimidine chemotherapy on quality of life in colorectal liver metastasis patients." Journal of Clinical Oncology 15, no. 5 (May 1997): 2022–29. http://dx.doi.org/10.1200/jco.1997.15.5.2022.

Texto completo
Resumen
PURPOSE Since systemic and regional (HAI) fluorinated pyrimidine chemotherapies offer similar survival benefit in treatment of colorectal liver metastases (CLM), we sought to identify their impact on quality of life (QoL), which might be a useful indicator of treatment preference. METHODS We compared QoL in 135 CLM patients managed by symptom control (n = 49 patients), systemic fluorouracil (5FU)/folinic acid (n = 35), or hepatic arterial floxuridine (FUDR) (n = 51). Full blood count and liver function tests, World Health Organization (WHO) toxicity criteria, and QoL (Rotterdam Symptom Checkli
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

Loprinzi, C. L., C. Ghosh, J. Camoriano, J. Sloan, P. D. Steen, J. C. Michalak, P. L. Schaefer, et al. "Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy." Journal of Clinical Oncology 15, no. 3 (March 1997): 1235–38. http://dx.doi.org/10.1200/jco.1997.15.3.1235.

Texto completo
Resumen
PURPOSE Stomatitis is a major dose-limiting toxicity of bolus fluorouracil (5FU)-based chemotherapy regimens, despite the use of oral cryotherapy. Pursuant to preliminary data that suggested a sucralfate oral solution could alleviate chemotherapy-induced oral mucositis, we developed a prospective trial to test this contention. PATIENTS AND METHODS A phase III, double-blind, placebo-controlled clinical trial was designed. Patients were entered onto the study at the time of the first cycle of 5FU-based chemotherapy. All patients received oral cryotherapy for 30 minutes with each dose of 5FU. In
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

Khairani, Sondang, Sesilia A. Keban, and Meyke Afrianty. "Evaluation of Drug Side Effects Chemotherapy on Quality of Life (QOL) Breast Cancer Patients at Hospital X in Jakarta." JURNAL ILMU KEFARMASIAN INDONESIA 17, no. 1 (April 24, 2019): 9. http://dx.doi.org/10.35814/jifi.v17i1.705.

Texto completo
Resumen
Breast cancer is the number one cancer type discovered at women in the world. Most causes are genetic factors and hormonal factors. One cancer treatments with chemotherapy. Chemotherapy drugs active in cells dividing and reproducing, but cells normally to be affected by chemotherapy and side effects from chemotherapy drugs affect quality of life. The aim of the study to evaluate side effects of chemotherapy drugs on the quality of life of breast cancer patients. Sampling technique observational prospective breast cancer patients with completed the chemotherapy cycle from September 2017 to Apri
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

El –Housseiny, Azza, Susan Saleh, Ashraf El –Masry, and Amany Allam. "Assessment of Oral Complications in Children Receiving Chemotherapy." Journal of Clinical Pediatric Dentistry 31, no. 4 (July 1, 2007): 267–73. http://dx.doi.org/10.17796/jcpd.31.4.cq752m6173142r28.

Texto completo
Resumen
The aim of this study was to assess the early oral complications in pediatric patients receiving chemotherapy. An interview and oral examination was conducted on 150 pediatric cancer patients receiving standard dose chemotherapy. Results showed that oral pain and dry mouth were the most frequent patients' complaints. The prevalences of chemotherapy-induced oral mucositis and oral infections were relatively high. The chemotherapeutic antimetabolites were the most frequently associated with oral complications than other types of chemotherapy. The present results indicate that the oral complicati
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Yang, James Chih-Hsin, Vera Hirsh, Martin Schuler, Nobuyuki Yamamoto, Kenneth J. O'Byrne, Tony S. K. Mok, Victoria Zazulina, et al. "Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations." Journal of Clinical Oncology 31, no. 27 (September 20, 2013): 3342–50. http://dx.doi.org/10.1200/jco.2012.46.1764.

Texto completo
Resumen
Purpose Patient-reported symptoms and health-related quality of life (QoL) benefits were investigated in a randomized, phase III trial of afatinib or cisplatin/pemetrexed. Patients and Methods Three hundred forty-five patients with advanced epidermal growth factor receptor (EGFR) mutation–positive lung adenocarcinoma were randomly assigned 2:1 to afatinib 40 mg per day or up to six cycles of cisplatin/pemetrexed. Lung cancer symptoms and health-related QoL were assessed every 21 days until progression using the European Organisation for Research and Treatment of Cancer Quality of Life Question
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Korytova, L. I., V. P. Sokurenko, E. A. Maslyukova, A. V. Meshechkin, N. D. Oltarzhevskaya, M. A. Korovina, I. V. Gusev, A. D. Kuznetsov, V. G. Krasnikova, and E. M. Obuhov. "EVALUATING THE EFFECTIVENESS OF THE COMBINED TREATMENT OF PATIENTS WITH COLORECTAL CANCER, BREAST CANCERAND CANCER OF THE FLOOR OF THE MOUTH USING A STERILE HYDROGEL MATERIAL "KOLEGEL 5-FTUR"." Russian Journal of Biotherapy 14, no. 4 (December 30, 2015): 99–103. http://dx.doi.org/10.17650/1726-9784-2015-14-4-99-103.

Texto completo
Resumen
The article is devoted to the effectiveness evaluation of the use of sterile material «Kolegel 5-ftur» on the basis of sodium alginate with 5-fluorouracil, as of shape of disk, in the course of chemoradiotherapy in patients with rectal cancer, breast cancer and cancer of the floor of the mouth. The study group included 38 patients: 19 patients diagnosed with CRR, 10 patients -BC, 9 patients - a cancer of the mouth floor. The study used a hydrogel material «Kolegel 5-ftur» during chemoradia- tion therapy for histologically confirmed diagnosis of a malignant tumor. The effectiveness of the combi
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

CAETANO, Rafael da Silva, Paula Gabrielle de CASTRO, Paulo Henrique de Souza CASTRO, Alexandre Meireles BORBA, Álvaro Henrique BORGES, and Luiz Evaristo Ricci VOLPATO. "Limitation of mouth opening after radiotherapy for head and neck." RGO - Revista Gaúcha de Odontologia 64, no. 1 (March 2016): 24–29. http://dx.doi.org/10.1590/1981-863720160001000032923.

Texto completo
Resumen
ABSTRACT Objective: To evaluate the ability to open the mouth in patients undergoing radiotherapy for head and neck and the variables related to this limitation. Methods: 32 patients were evaluated six months after completion of radiotherapy sessions to treat cancer in the head and neck. The maximum mouth opening was measured using digital calipers and its association with gender, age, smoking, alcohol consumption, tumor location, chemotherapy and surgery were analyzed using the Mann-Whitney and Kruskal-Wallis tests at a level of significance of 95%. Results: The mean age of patients was 60.44
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

Wilson, S. Darsana, Chitra C. Nair, Christy Johns, Christy Mathew, Dani Joseph, and Precilla DSilva. "A Correlational Study on Taste Alterations and Quality of Life Among Cancer Patients." Journal of Health and Allied Sciences NU 11, no. 03 (April 15, 2021): 147–53. http://dx.doi.org/10.1055/s-0041-1726574.

Texto completo
Resumen
Abstract Introduction One of the major problems faced by the world today is cancer. Cancer is an abnormal growth of cells. Chemotherapy, surgery, and radiation therapy are the treatment regimen for cancer. Prolonged use of chemotherapy drugs can cause different side effects such as alopecia, weight loss, sexual dysfunction, mood swings, and the most important one is taste alterations. The aim of the study is to determine the taste alterations (TAs) and quality of life (QOL) among cancer patients who have undergone three cycles of chemotherapy. Methods The approach used is descriptive survey de
Los estilos APA, Harvard, Vancouver, ISO, etc.
11

Ivanova, Kristīne, and Marija Avota. "Antineoplastic Drugs: Occupational Exposure and Side Effects." Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. 70, no. 5 (October 1, 2016): 325–29. http://dx.doi.org/10.1515/prolas-2016-0049.

Texto completo
Resumen
Abstract Due to their adverse effects, antineoplastic drugs (cancer chemotherapy drugs) are considered as a potential health risk for nurses and nursing assistants. The aim of this study was to review and summarise information about acute side effects of antineoplastic drugs in two major cancer centres in Latvia. In total 51 nurses and nursing assistants participated in the study, all working in chemotherapy ward at least for 12 months. The research was conducted in Pauls Stradiņš Clinical University Hospital and Rīga East University Hospital, Oncology Centre of Latvia. 56.86% of respondents r
Los estilos APA, Harvard, Vancouver, ISO, etc.
12

Milazzo, John, Mirseyed A. Mohit-Tabatabai, George J. Hill, Suresh Raina, Anangur Swaminathan, Nae K. Cheung, Kumar Dasmahapatra, and Benjamin F. Rush. "Preoperative intra-arterial infusion chemotherapy for advanced squamous cell carcinoma of the mouth and oropharynx." Cancer 56, no. 5 (September 1, 1985): 1014–17. http://dx.doi.org/10.1002/1097-0142(19850901)56:5<1014::aid-cncr2820560506>3.0.co;2-9.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
13

Ishii, A., Y. Korogi, T. Hirai, R. Nishimura, R. Murakami, I. Ikushima, K. Kawanaka, M. Shinohara, and Y. Yamashita. "Intraarterial infusion chemotherapy and conformal radiotherapy for cancer of the mouth: prediction of the histological response to therapy with magnetic resonance imaging." Acta Radiologica 48, no. 8 (October 2007): 900–906. http://dx.doi.org/10.1080/02841850701501741.

Texto completo
Resumen
Background: Although intraarterial chemotherapy has been used to treat head and neck cancers, some cases have shown poor response. If we can predict the response to this therapy on MRI, individual treatment plans may be altered to the most appropriate form of treatment. Purpose: To evaluate whether MRI can predict the histological response to preoperative chemoirradiation in patients with cancer of the mouth. Material and Methods: This study comprised of 29 consecutive patients with 30 oral cancers. All patients underwent tumor resection after intraarterial infusion chemotherapy and conformal
Los estilos APA, Harvard, Vancouver, ISO, etc.
14

Yunus, Barunawaty. "Efek samping terapi radiasi penderita kanker kepala dan leher pada kelenjar saliva." Journal of Dentomaxillofacial Science 7, no. 1 (April 30, 2008): 57. http://dx.doi.org/10.15562/jdmfs.v7i1.194.

Texto completo
Resumen
Nasopharyngeal cancer has different malignancy types, based on its location. Themost frequent type of nasopharyngeal cancer is carcinoma of squamous cell whichhappens on cells inside nose, mouth, and throat. The rare types happened such assalivary gland tumor, lymphoma, and sarcoma. There are three main therapies totreat nasopharyngeal cancer; they are radiation therapy, surgery, and chemotherapy.The main treatment is radiation therapy or surgery and chemotherapy or combinationboth of them. Chemotherapy is often conducted as an additional treatment.Combination treatment between those three tre
Los estilos APA, Harvard, Vancouver, ISO, etc.
15

Xie, Congying, Meng Su, and Xiance Jin. "Apatinib as a salvage treatment in gynecologic cancer patients failed from two or more lines of prior chemotherapy." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e17009-e17009. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e17009.

Texto completo
Resumen
e17009 Background: The aim of this study was to evaluate the efficacy and safety of apatinib, an oral VEGFR2 inhibitor, in the treatment of advanced cervical and ovarian cancer patients who failed from two or more lines of chemotherapy. Methods: The advanced cervical and ovarian cancer patients, who experienced two or more lines of chemotherapy and treated with apatinib from April 2015 to January 2017, were retrospectively reviewed. All eligible patients received continuous apatinib treatment until disease progression, death, or intolerable toxicity. Survival and toxicities outcome were evalua
Los estilos APA, Harvard, Vancouver, ISO, etc.
16

Brown, Carlton G., Deborah B. McGuire, Douglas E. Peterson, Susan L. Beck, William N. Dudley, and Kathleen H. Mooney. "The Experience of a Sore Mouth and Associated Symptoms in Patients With Cancer Receiving Outpatient Chemotherapy." Cancer Nursing 32, no. 4 (July 2009): 259–70. http://dx.doi.org/10.1097/ncc.0b013e3181a38fc3.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
17

Da Ponte, G., J. Rato, C. Pinto, M. Lobo, and S. Ouakinin. "Bruxism as a Consequence of Chemotherapy?" European Psychiatry 41, S1 (April 2017): S668. http://dx.doi.org/10.1016/j.eurpsy.2017.01.1140.

Texto completo
Resumen
IntroductionBruxism is a syndrome with uncertain etiology but with proposed factors: psychosocial, peripheral and central. Treatment is also controversial and one of the options focuses in GABA theory and regularization of ion channels. Xelox (capecitabine + oxaliplatin) and bevacizumad is indicated for metastatic colorectal cancer, being oxaliplatin the most neurotoxic agent (acute syndrome and/or a chronic sensory neuropathy). Acute neurotoxicity is very frequent and it is a sensory and/or a motor toxicity (as tongue tingling or jaw spams). The proposed pathogenesis – neuronal hyperexcitabil
Los estilos APA, Harvard, Vancouver, ISO, etc.
18

Kris, M. G., R. J. Gralla, R. A. Clark, and L. B. Tyson. "Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy." Journal of Clinical Oncology 6, no. 4 (April 1988): 659–62. http://dx.doi.org/10.1200/jco.1988.6.4.659.

Texto completo
Resumen
GR-C507/75 (GR38032F) antagonizes the 5-HT3 (serotonin) receptor and prevents cisplatin-induced emesis in animals. In this dose-ranging trial, 44 patients with cancer receiving chemotherapy known to produce nausea and vomiting (including cisplatin, cyclophosphamide, and doxorubicin) received three intravenous (IV) infusions of GR-C507/75 every two hours beginning 30 minutes before chemotherapy. Ten dosage levels were explored, ranging from 0.04 mg/kg to 0.35 mg/kg in each of the three infusions. Toxicities were mild and included sedation, dizziness, headache, transient elevations of SGOT or al
Los estilos APA, Harvard, Vancouver, ISO, etc.
19

Lyanova, A. A., L. Yu Vladimirova, E. M. Frantsiyants, I. V. Neskubina, M. A. Engibaryan, N. A. Abramova, I. L. Popova, et al. "Dynamics of changes in type 1 and 2 insulinlike growth factors in the blood of patients with oral squamous cell cancer after targeted therapy with cetuximab." Malignant tumours 11, no. 1 (July 26, 2021): 29–36. http://dx.doi.org/10.18027/2224-5057-2021-11-1-29-36.

Texto completo
Resumen
Objective. Studying the blood levels of type 1 and 2 insulin-like growth factors in patients with squamous cell carcinoma of the tongue and mouth floor mucosa depending on the therapy effect.Materials and Methods. The study included data from 30 patients with squamous cell carcinoma of the tongue and mouth floor mucosa T3–4N0–1M0 who received chemotherapy cycles together with targeted therapy with cetuximab. Twenty non-cancer donors were examined as well. Depending on the therapy effect, patients were divided into two groups: sensitive and resistant ones.Results. Initial levels of IGF-1 and IG
Los estilos APA, Harvard, Vancouver, ISO, etc.
20

Nicolatou-Galitis, Ourania, and Amanda Psyrri. "Trismus and reduced quality of life in patients with oral squamous cell carcinoma who received postoperative radiotherapy alone or combined with chemotherapy." Journal of Clinical Oncology 35, no. 31_suppl (November 1, 2017): 222. http://dx.doi.org/10.1200/jco.2017.35.31_suppl.222.

Texto completo
Resumen
222 Background: Patients, who receive radiotherapy (RT) for head and neck cancer, develop chronic functional abnormalities and reduced mouth opening-trismus, surviving with reduced quality of life (QoL). We aimed to study trismus and QoL in patients with oral cancer, who received post-operative radiotherapy or chemoradiotherapy. Methods: Patients, who receive radiotherapy (RT) for head and neck cancer, develop chronic functional abnormalities and reduced mouth opening-trismus, surviving with reduced quality of life (QoL). We aimed to study trismus and QoL in patients with oral cancer, who rece
Los estilos APA, Harvard, Vancouver, ISO, etc.
21

WAECHTER, Janine, Cristina Braga XAVIER, Gislene CORRÊA, Eduardo de Freitas GOMES, and Romeu Belon FERNANDES FILHO. "Oral and maxillofacial rehabilitation of a patient suffering from intraosseous adenoid cystic carcinoma." RGO - Revista Gaúcha de Odontologia 65, no. 2 (June 2017): 168–73. http://dx.doi.org/10.1590/1981-863720170002000122977.

Texto completo
Resumen
ABSTRACT Treatment of cancers of the head and neck may provoke sequelae that affect the quality of life of patients during and after treatment. Mouth-sinus communication resulting from partial or total surgical resection of the palate leads to the patient experiencing dysphagia, dysphonia and trismus, which can lead to social isolation of the individual. As a result, the work of the dental surgeon, together with the multidisciplinary team caring for cancer patients, is fundamental and can help with the diagnosis, assist in the management of chemotherapy and radiotherapy complications and enabl
Los estilos APA, Harvard, Vancouver, ISO, etc.
22

Ellis, Georgiana K., Robert B. Livingston, Julie R. Gralow, Stephanie J. Green, and Tove Thompson. "Dose-Dense Anthracycline-Based Chemotherapy for Node-Positive Breast Cancer." Journal of Clinical Oncology 20, no. 17 (September 1, 2002): 3637–43. http://dx.doi.org/10.1200/jco.2002.12.113.

Texto completo
Resumen
PURPOSE: Theoretical considerations and clinical experience suggest that dose-dense chemotherapy may be superior to other approaches using the same drugs. We studied a dose-dense combination of doxorubicin and cyclophosphamide, with or without fluorouracil, as adjuvant therapy. PATIENTS AND METHODS: Patients with resected breast cancer were treated if they were node-positive and estrogen receptor–negative, positive for overexpression of Her-2-neu, or had four or more involved nodes. Doxorubicin was given weekly to a total dose of 480 mg/m2. Cyclophosphamide 60 mg/m2 was given daily by mouth du
Los estilos APA, Harvard, Vancouver, ISO, etc.
23

Aljeboory, Ali A. H., and Nazhat M. Abdlkareem Al-Zubaidi. "Loranthus Europaeus is an Alternative Medicine in Treatment of Cyst and Mouth Inflammation Resulted from Chemotherapy of Breast Cancer." International Journal of Drug Delivery Technology 10, no. 01 (March 25, 2020): 183–86. http://dx.doi.org/10.25258/ijddt.10.1.32.

Texto completo
Resumen
The natural product continues to be important as a source of novel drugs because these drugs do not need a sophisticated instrument, cheap resources, less toxic, no resistance to them by bacteria compared with the synthetic drugs. However, the natural product will continue to be important in addition in three areas of discovery, they are a target for production by biotechnology, as source of new lead compounds of a novel chemical structure and as the active ingredients of useful treatments divided from traditional systems of folkloric medicine.1 The herb Loranthus Europaeus leaves, and fruits
Los estilos APA, Harvard, Vancouver, ISO, etc.
24

Macedo, Taysa B. C., Silvia T. Elias, Hianne M. Torres, Fernanda Paula Yamamoto-Silva, Dâmaris Silveira, Pérola O. Magalhães, Adriana Lofrano-Porto, Eliete N. S. Guerra, and Maria Alves G. Silva. "Cytotoxic Effect of Erythroxylum suberosum Combined with Radiotherapy in Head and Neck Cancer Cell Lines." Brazilian Dental Journal 27, no. 1 (February 2016): 108–12. http://dx.doi.org/10.1590/0103-6440201600014.

Texto completo
Resumen
Abstract The mouth and oropharynx cancer is the 6th most common type of cancer in the world. The treatment may involve surgery, chemotherapy and radiotherapy. More than 50% of drugs against cancer were isolated from natural sources, such as Catharanthus roseus and epipodophyllotoxin, isolated from Podophyllum. The biggest challenge is to maximize the control of the disease, while minimizing morbidity and toxicity to the surrounding normal tissues. The Erythroxylum suberosum is a common plant in the Brazilian Cerrado biome and is popularly known as "cabelo-de-negro". The objective of this study
Los estilos APA, Harvard, Vancouver, ISO, etc.
25

Fort, Pauline, Blandine Marsault, Antoine Hertzog, Emilie Dubost, Jean-Marc Tourani, and Isabelle Princet. "Use of complementary medicines by patients treated with chemotherapy: Survey in a French day care unit." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): e19555-e19555. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e19555.

Texto completo
Resumen
e19555 Background: Nowadays, communication about alternative medicines and biologic therapies is very intense. Anyone can find information, more or less scientific, on internet, television or magazines. Therefore, patients treated with chemotherapy may use many complementary medicines. The purpose of our study is to do a summary of the use of those alternative therapies by our patients in order to evaluate the potential risk of interference with their antitumor treatment. Methods: We carried out a prospective study among patients in the day care unit. During an interview, they were asking for
Los estilos APA, Harvard, Vancouver, ISO, etc.
26

Karpenko, A. V., R. R. Sibgatullin, A. A. Boyko, M. G. Kostova, O. M. Nikolayeva, and E. M. Trunin. "Dynamics of quality of life of head and neck cancer patients after treatment. Clinical significance." Head and neck tumors (HNT) 8, no. 4 (January 13, 2019): 39–47. http://dx.doi.org/10.17650/2222-1468-2018-8-4-39-47.

Texto completo
Resumen
The study objective is to evaluate the quality of life as one of the main parameters that determines the effectiveness of treatment of patients with head and neck squamous cell carcinoma.Materials and methods. Thirty-three stage III—IV oral cancer patients aged between 39 and 70 years were asked to fill EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30-questions) and QLQ-H&amp;N35 (head and neck cancer-specific module) before and 12—18 months after completion of the treatment that consisted of surgery followed by radiation with or w
Los estilos APA, Harvard, Vancouver, ISO, etc.
27

Grau, J. J., M. Caballero, E. Verger, and J. L. Blanch. "Actual proportion of patients (pts) receiving chemotherapy or cetuximab for head and neck squamous carcinoma (HNSC)." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): e17058-e17058. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e17058.

Texto completo
Resumen
e17058 Background: With the new indications of chemotherapy or cetuximab in HNSC, the rate of pts receiving these therapies nowadays is unclear. Methods: This retrospective study identified all consecutive pts with HNSC from January 1, 2006, to December 31, 2007, presented in a multidisciplinary team to decide further treatment in a single institution. ASCO guidelines for larynx preservation were followed to select surgery or chemoradiotherapy (ChRt). We classified the intention-to-treat as palliative, adjuvant or induction therapy. In the last case, always with concomitant radiotherapy (Rt) o
Los estilos APA, Harvard, Vancouver, ISO, etc.
28

Ohmae, Masatoshi, Itsuro Kato, Yusei Fujita, Hiroo Takaoka, Noritoshi Meshii, Ayako Takasu, and Mitsuhiro Nakazawa. "Outpatient intra-arterial chemotherapy without radiation therapy for stages II and III oral cancer: A new treatment to improve quality of life and reduce irradiation-related complications." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e17567-e17567. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e17567.

Texto completo
Resumen
e17567 Background: We developed a superselective intra-arterial chemotherapy (iaCT) approach to oral cancer, in which an intra-arterial catheter is retrogradely inserted through the superficial temporal artery and/or occipital artery with concurrent radiation therapy (RT). This approach remarkably improves the curative effect, but it decreases patients’ quality of life (QOL) because of prolonged hospitalization, severe stomatitis, lifelong dry mouth, dysgeusia, and radiation osteonecrosis of the maxillo-mandibular bone. Methods: This study assessed our new outpatient iaCT (op-iaCT) approach in
Los estilos APA, Harvard, Vancouver, ISO, etc.
29

Soliman, Hanan Mohamed Mohamed. "The effect of cryotherapy on chemotherapy induced oral mucositis in Egyptian cancer patients: A randomized controlled trial." Journal of Nursing Education and Practice 9, no. 11 (August 26, 2019): 63. http://dx.doi.org/10.5430/jnep.v9n11p63.

Texto completo
Resumen
Background and objective: Oral Mucositis (OM) is a common adverse side-effect caused by cancer treatments (chemotherapy and/or radiotherapy). And can lead to mucosa toxicity. Patients with OM may experience extreme pain and may not be able to eat, drink and talk and, as a result, their quality of life is impaired. Treatment and prevention of OM in adult patients treated with chemotherapy are challenging issues for health care professionals. The aim of this study was to evaluate the effect of cryotherapy on incidence and severity of chemotherapy-induced OM and OM related pain in patients treate
Los estilos APA, Harvard, Vancouver, ISO, etc.
30

Friese, Christopher Ryan, Philip J. Stella, Beth Lavasseur, Paul T. Adams, Lauren Swafford, JoAnn Lewis, and Kari Michigan Mendelsohn-Victor. "Frequency and burden of patient-reported chemotherapy toxicities in community-based oncology practices." Journal of Clinical Oncology 32, no. 31_suppl (November 1, 2014): 178. http://dx.doi.org/10.1200/jco.2014.32.31_suppl.178.

Texto completo
Resumen
178 Background: Patient-reported outcomes measurement is recommended to improve care delivery. Toxicities are important to study given their impacts on treatment completion. We captured patient-reported toxicities in community-based oncology practices and identified toxicities associated with excess health care service use. Methods: We surveyed newly-diagnosed patients who completed their first chemotherapy cycle at 5 community practices. Exclusion criteria were prior cancer history, non-English speakers, psychiatric diagnosis, and clinical trial participation. At the second cycle return visit
Los estilos APA, Harvard, Vancouver, ISO, etc.
31

LeBlanc, Thomas William, Steven Wolf, Debra M. Davis, Greg Samsa, Susan C. Locke, Karen E. Steinhauser, Peter A. Ubel, James A. Tulsky, and Amy Pickar Abernethy. "Symptom burden, quality of life, and distress in acute myeloid leukemia patients receiving induction chemotherapy: A prospective electronic patient-reported outcomes study." Journal of Clinical Oncology 32, no. 31_suppl (November 1, 2014): 167. http://dx.doi.org/10.1200/jco.2014.32.31_suppl.167.

Texto completo
Resumen
167 Background: Induction chemotherapy for acute myeloid leukemia (AML) is more intensive than many solid tumor treatments, and may be associated with a different symptom burden. Little is known about the most prevalent symptoms during AML induction, nor how they change over time. Methods: We enrolled AML inpatients at initiation of induction chemotherapy, and assessed their symptoms, quality of life (QoL), and distress weekly during their month-long hospitalization for treatment, using 3 validated instruments: Patient Care Monitor v2.0 (PCM); Functional Assessment of Cancer Therapy–Leukemia (
Los estilos APA, Harvard, Vancouver, ISO, etc.
32

Panattoni, Laura Elizabeth, Salene M. W. Jones, Kaylin J. Bolt, Karma L. Kreizenbeck, Annika Ittes, and Scott David Ramsey. "Patient and provider perceptions of emergency room visits during chemotherapy." Journal of Clinical Oncology 37, no. 27_suppl (September 20, 2019): 183. http://dx.doi.org/10.1200/jco.2019.37.27_suppl.183.

Texto completo
Resumen
183 Background: Emergency room (ER) visits during chemotherapy are costly. To identify potential causes of ER visits, we interviewed oncology patients and providers about symptoms and other factors related to ER visits. Methods: People with cancer (n = 19) and oncology physicians and nurses (n = 11) were interviewed using a semi-structured protocol. Interviews were transcribed. The study team developed a codebook and interviews were coded deductively. Four of the interviews were double coded. Results: Patients reported communicating with their physicians mostly by telephone. Patients reported
Los estilos APA, Harvard, Vancouver, ISO, etc.
33

Navari, R. M., L. H. Einhorn, P. J. Loehrer, S. D. Passik, J. Vinson, J. McClean, N. Chowhan, N. Hanna, C. Calley, and M. Yu. "A phase II trial of olanzapine and palonosetron for the prevention of chemotherapy induced nausea and vomiting (CINV)." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 8608. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.8608.

Texto completo
Resumen
8608 Background: Olanzapine has been shown to be a safe and effective agent for the prevention of CINV in chemotherapy naïve cancer patients. Palonosetron has been approved for the prevention of acute CINV and for the prevention of delayed CINV in patients receiving moderately emetogenic chemotherapy (MEC). Methods: A phase II trial was performed for the prevention of CINV in chemotherapy naïve patients using the combination of olanzapine and palonosetron. The regimen was 10 mg of oral olanzapine, 0.25 mg of intravenous palonosetron, and dexamethasone (20 mg for highly emetogenic and 8 mg for
Los estilos APA, Harvard, Vancouver, ISO, etc.
34

Pendharkar, D., S. Gupta, M. K. Pal, S. Hakim, and T. Rashid. "Feasibility of combining humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 (nimotuzumab) with chemotherapy-A study of toxicity profile and tolerance." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 14151. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.14151.

Texto completo
Resumen
14151 Background. Anti-EGFR antibodies have been approved in combination with radiotherapy for the treatment of head and neck squamous cell carcinoma(SCCHN) and being tried in glioblastoma multiforme(GBM). The overall toxicity profile is tolerable. There is no data available on Humanized Anti EGFR antibody in combination with chemotherapeutic agents. Nimotuzumab, the humanized MAb derived from ior EGFR/R3, is a genetically engineered IgG1, with high affinity and specificity to EGFR. This study was undertaken to record the immediate and early toxicity of combining Nimotuzumab with various chemo
Los estilos APA, Harvard, Vancouver, ISO, etc.
35

Dodd, M. J., M. Cho, C. Miaskowski, and J. Quivey. "A longitudinal evaluation of oral mucositis in patients receiving radiation therapy (IMRT) with/without chemotherapy (CTX)." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): e20572-e20572. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e20572.

Texto completo
Resumen
e20572 Background: Oral mucositis is a major side effect of RT ± CTX to the head and neck. A variety of instruments and techniques have been used to quantify oral cavity changes during treatment. Few studies have reported on the evaluation of oral mucositis using both subjective and objective methods. A secondary aim in our study testing an innovative mouthwash is to increase our understanding of using subjective and objective methods for measuring oral mucositis, functional status, and weight changes over time. Methods: Patients reported functional status, pain and investigators measured oral
Los estilos APA, Harvard, Vancouver, ISO, etc.
36

Johnson, N. "Quantifying the Immense Burden of OPMDS and of Oral Cancer in South Asia: Time for Action." Journal of Global Oncology 4, Supplement 2 (October 1, 2018): 125s. http://dx.doi.org/10.1200/jgo.18.20600.

Texto completo
Resumen
Background: Cancer of head and neck is sixth most common malignancy worldwide https://www.ncbi.nlm.nih.gov/pubmed/27245686 . ∼90% are squamous cell carcinomas [HNSCC]. Of H&amp;N sites, mouth is most common [∼300,373 cases pa, cf oropharynx ∼142,387; larynx ∼156,877; nasopharynx 86,691]. Across south Asia, cancer of lip &amp; mouth [oral cancer: OSCC] is a serious public health problem. In many, it is the most common cancer among men, 5th/6th in women, second overall. Five year survival rates are &lt; 50%. Treatment is devastating. It is difficult to get authorities and public to recognize the
Los estilos APA, Harvard, Vancouver, ISO, etc.
37

Hussain, Syed Md Akram. "Comprehensive update on cancer scenario of Bangladesh." South Asian Journal of Cancer 02, no. 04 (October 2013): 279–84. http://dx.doi.org/10.4103/2278-330x.119901.

Texto completo
Resumen
AbstractBangladesh, at 142 million people, is the ninth most populous country in the world. There are 13 to 15 lakh cancer patients in Bangladesh, with about two lakh patients newly diagnosed with cancer each year. As an overview, lung cancer and mouth-oropharynx cancer rank as the top two prevalent cancers in males. Other types of cancers are esophagus cancer and stomach cancer. In women, cancer cervix uteri and breast cancer are most prevalent. Other cancer types, which affect women, are mouth and oropharynx cancer, lung cancer, and esophagus cancer. There are around 150 qualified clinical o
Los estilos APA, Harvard, Vancouver, ISO, etc.
38

Rivkin, S. E., S. Green, B. Metch, A. B. Cruz, M. D. Abeloff, W. R. Jewell, J. J. Costanzi, W. B. Farrar, J. P. Minton, and C. K. Osborne. "Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study." Journal of Clinical Oncology 12, no. 10 (October 1994): 2078–85. http://dx.doi.org/10.1200/jco.1994.12.10.2078.

Texto completo
Resumen
PURPOSE To compare chemohormonal therapy, chemotherapy alone, and hormonal therapy alone in postmenopausal patients with estrogen receptor (ER)-positive operable breast cancer and positive axillary nodes with respect to survival and disease-free survival (DFS). PATIENTS AND METHODS Eight hundred ninety-two postmenopausal women with ER-positive, node-positive breast cancer were enrolled by the Southwest Oncology Group (SWOG) from July 1979 to March 1989 and 74 by the Eastern Cooperative Oncology Group (ECOG) between June 1987 and March 1989. Patients were stratified according to number of invol
Los estilos APA, Harvard, Vancouver, ISO, etc.
39

Srinivas, Mangala, Ravichandra Volabailu, Jayarama Shetty K., and Sangeeta Nath Sharma. "A study on management of oral cancer in a tertiary care hospital." International Journal of Basic & Clinical Pharmacology 7, no. 2 (January 23, 2018): 278. http://dx.doi.org/10.18203/2319-2003.ijbcp20180098.

Texto completo
Resumen
Background: Oral cancers form nearly 30% of the cancers. The most effective way of combating oral cancer is by early diagnosis followed by concurrent chemo-radiotherapy which is the most popular approach in current practice. The adverse effects seen in oral cancer patient’s due to their treatment are nausea &amp; vomiting, mucositis, constipation, diarrhoea, fatigue &amp; radiation dermatitis. Polypharmacy is due to variety of treatment options in oral cancer patients, which needs to be addressed.Methods: Over a period of 18 months, the in-patient records of 79 patients with oral cancers, admi
Los estilos APA, Harvard, Vancouver, ISO, etc.
40

del Giglio, Adriana Braz, Tatiana Goberstein Lerner, Henrique Soares Paiva, Renata Guise Soares Azevedo, Ricardo tuma Guariento, Cecilia Goldman, Bruno Carelli, et al. "Purified dry extract of Paullinia cupana (guaraná) (PC-18) for chemotherapy-related fatigue in patients with solid tumors: An early discontinuation study." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): e20680-e20680. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e20680.

Texto completo
Resumen
e20680 Background: Paullinia cupana (guaraná) is an Amazonian plant that has been previously shown to be effective in treating chemotherapy-related fatigue (CRF) in patients with breast cancer. We aimed to evaluate the efficacy of a purified dry extract of P. cupana (PC-18) in patients with various solid tumors treated with chemotherapy. Methods: We included 40 patients with solid tumors who showed increases in their Brief Fatigue Inventory (BFI) questionnaire scores after one week of systemic chemotherapy. PC-18 was administered at 37.5 mg by mouth two times per day (PO bid), starting after o
Los estilos APA, Harvard, Vancouver, ISO, etc.
41

Hoppe, C., S. Kutschan, J. Dörfler, J. Büntzel, J. Büntzel, and Jutta Huebner. "Zinc as a complementary treatment for cancer patients: a systematic review." Clinical and Experimental Medicine 21, no. 2 (January 26, 2021): 297–313. http://dx.doi.org/10.1007/s10238-020-00677-6.

Texto completo
Resumen
AbstractZinc is a trace element that plays an important role in the immune system and cell growth. The role of zinc in cancer treatment has been discussed for some time, however without reaching an evidenced-based consensus. Therefore, we aim to critically examine and review existing evidence on the role of zinc during cancer treatment. In January 2019, a systematic search was conducted searching five electronic databases (Embase, Cochrane, PsychINFO, CINAHL and PubMed) to find studies concerning the use, effectiveness and potential harm of zinc therapy on cancer patients. Out of initial 5244
Los estilos APA, Harvard, Vancouver, ISO, etc.
42

Bolton, Laura. "Managing Oral Mucositis in Patients With Cancer." Wounds : a compendium of clinical research and practice 33, no. 5 (May 10, 2021): 136–38. http://dx.doi.org/10.25270/wnds/2021.136138.

Texto completo
Resumen
Patients with oral mucositis (OM) have inflamed epithelial lesions of the mouth that progress to form painful ulcerations with submucosal hemorrhaging and infection. Oral mucositis makes it painful to eat, drink, and speak, resulting in distress, weight loss, and declining health. These symptoms occur in up to 40% of patients within 5 to 10 days after beginning chemotherapy (CT), and in nearly all patients within 1 to 2 weeks of starting radiotherapy (RT) for head and neck cancer. Oral mucositis can be severe enough to interrupt treatment and reduce survival rates. In 2014, the Mucositis Guide
Los estilos APA, Harvard, Vancouver, ISO, etc.
43

Rangineni, Srikrishnadevarayulu, Debarshi Lahiri, Biplab Misra, Tapas Maji, Sanjoy Roy, Dilip Kumar Ray, Saptarshi Banerjee, Subhadip Das, and Ashwin Mohandas Pallath. "Hypofractionated intensity-modulated radiation therapy with concurrent cisplatin in locally advanced oropharyngeal cancer: feasibility experience from a Government cancer centre of Eastern India in a resource-constrained setting." Journal of Radiotherapy in Practice 19, no. 1 (May 29, 2019): 59–64. http://dx.doi.org/10.1017/s1460396919000323.

Texto completo
Resumen
AbstractPurpose:Radiation therapy (RT), in combination with chemotherapy, is the mainstay in the treatment for locally advanced oropharyngeal cancer. We analysed the tumour response and the toxicity profiles in patients having locally advanced oropharyngeal cancers receiving hypofractionated intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy with Cisplatin investigating the feasibility and radiobiological efficacy of the regimen, along with its use as a resource-sparing alternative for a high-volume centre.Material and Methods:The records of 41 eligible patients with loca
Los estilos APA, Harvard, Vancouver, ISO, etc.
44

Galitis, Evangelos, Vyron Droukas, Michail Tzakis, Vassileios Psarras, Dimitra Galiti, Eythymios Kyrodimos, Miltiadis Trichas, et al. "Trismus and reduced quality of life in patients with oral squamous cell carcinoma, who received post-operative radiotherapy alone or combined with chemotherapy." Forum of Clinical Oncology 8, no. 1 (June 30, 2017): 29–36. http://dx.doi.org/10.1515/fco-2015-0023.

Texto completo
Resumen
Abstract Background Patients, who receive radiotherapy (RT) for head and neck cancer, develop chronic functional abnormalities and survive with reduced quality of life. Purpose We aimed to study patients with oral cancer, who received post-operative radiotherapy or chemoradiotherapy. Patients Ten patients (mean age 63.8 years) were included. Methods Oral mucositis, pain and xerostomia, maximum mouth opening (MMO) and functional abnormalities before and after RT were recorded. The 35 mm MMO or less was accepted as trismus. Patients completed the EORTC QLQ C-30 and Head/Neck35 questionnaires. Re
Los estilos APA, Harvard, Vancouver, ISO, etc.
45

Bown, Stephen G. "Photodynamic therapy for photochemists." Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences 371, no. 1995 (July 28, 2013): 20120371. http://dx.doi.org/10.1098/rsta.2012.0371.

Texto completo
Resumen
Photodynamic therapy (PDT) is an evolving technique for localized control of diseased tissue with light after prior administration of a photosensitizing agent and in the presence of oxygen. The biological effect is quite different from surgery, radiotherapy and chemotherapy. With no temperature change during treatment, connective tissues like collagen are largely unaffected, so maintaining the mechanical integrity of hollow organs. PDT is of particular value for pre-cancer and early cancers of the skin (not melanomas) and mouth as the cosmetic and functional results are so good. Another key in
Los estilos APA, Harvard, Vancouver, ISO, etc.
46

Zheng, Wang Fang, and Chuner Jiang. "Treatment outcomes of 257 patients with locally advanced nasopharyngeal carcinoma treated with nimotuzumab plus intensity-modulated radiotherapy with or without chemotherapy: A single institution experience." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 6079. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.6079.

Texto completo
Resumen
6079 Background: To report the long-term outcome and toxicitie of locally advanced nasopharyngeal carcinoma (NPC) treated with nimotuzumab plus intensity- modulated radiotherapy (IMRT) with or without chemotherapy. Methods: From October 2009 to March 2014, 257 newly histology-proven, non-metastatic NPC patients were retrospectively enrolled. They are aged 10-76 years. The distribution of disease was stage III in 150 (58.4%), stage IV A in 88 (34.2%), and stage IV B in 19 (7.4%). All the patients received the treatment of nimotuzumab plus IMRT, and 239 cases were used for cisplatin-based chemot
Los estilos APA, Harvard, Vancouver, ISO, etc.
47

Zhang, Lingyun, Xiujuan Qu, Yuee Teng, Jing Shi, Ping Yu, Tao Sun, Jingyan Wang, et al. "Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study)." Journal of Clinical Oncology 35, no. 31 (November 1, 2017): 3558–65. http://dx.doi.org/10.1200/jco.2017.72.2538.

Texto completo
Resumen
Purpose We examined the efficacy and safety of thalidomide (THD) for the prevention of delayed nausea and vomiting in patients who received highly emetogenic chemotherapy (HEC). Patients and Methods In a randomized, double-blind, active-controlled, phase III trial, chemotherapy-naive patients with cancer who were scheduled to receive HEC that contained cisplatin or cyclophosphamide-doxorubicin/epirubincin ≥ 50 mg/m2 regimens were randomly assigned to a THD group (100 mg twice daily on days 1 to 5) or placebo group, both with palonosetron (0.25 mg on day 1) and dexamethasone (12 mg on day 1; 8
Los estilos APA, Harvard, Vancouver, ISO, etc.
48

List, M. A., E. E. Vokes, E. W. Cohen, K. M. Stenson, T. Karrison, B. E. Bruce, M. Witt, and D. J. Haraf. "Performance and side effect evaluation of sequentially reduced radiotherapy doses in a phase II trial of induction chemotherapy (IndCT) followed by concomitant chemoradiotherapy (CTX) for advanced head and neck cancer (HNC)." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 5558. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.5558.

Texto completo
Resumen
5558 Background: CTX regimens are often limited by severe acute toxicities and long-term functional impairment. This paper presents patient (pt) reported side effects and performance outcome in 3 sequential groups of stage IV HNC pts treated at the University of Chicago with IndCT and lowering radiation doses with the goal of maintaining survival while minimizing negative sequelae. Methods: Pts. were treated with IndCT followed by alternating weeks of concurrent CTX with lowering doses of radiotherapy to gross disease/ high risk microscopic/low risk microscopic disease: Group A - 75/60/45 Gy (
Los estilos APA, Harvard, Vancouver, ISO, etc.
49

Sailors, Mary H., Xin Shelley Wang, Ping Liu, Valen E. Johnson, James M. Reuben, Evan N. Cohen, Loretta A. Williams, Tito R. Mendoza, and Charles S. Cleeland. "Longitudinal relationship between inflammatory markers and patient-reported symptom severity during induction therapy for multiple myeloma." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 9083. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.9083.

Texto completo
Resumen
9083 Background: Multiple myeloma (MM) patients undergoing induction therapy experience both disease- and therapy-related symptoms. We investigated the association between the trajectory of symptom severity and changes in levels of inflammatory markers. Methods: MM patients (N=62) rated symptoms via the M. D. Anderson Symptom Inventory (MDASI) twice a week during induction therapy. Patients contributed serum samples before the start of every chemotherapy cycle. A panel of pro- and anti-inflammatory cytokines and markers was evaluated by Luminex. Ordinal regression analyses were used to describ
Los estilos APA, Harvard, Vancouver, ISO, etc.
50

Johnson, D. H., F. A. Greco, J. Strupp, K. R. Hande, and J. D. Hainsworth. "Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial." Journal of Clinical Oncology 8, no. 10 (October 1990): 1613–17. http://dx.doi.org/10.1200/jco.1990.8.10.1613.

Texto completo
Resumen
Twenty-two patients with recurrent small-cell lung cancer (SCLC) were treated with single-agent etoposide 50 mg/m2/d by mouth for 21 consecutive days. Eleven patients had received previous chemotherapy with cyclophosphamide, doxorubicin, and vincristine (CAV) or etoposide (CAE) or both (CAVE). Four of the latter patients also received salvage treatment with cisplatin and etoposide (EP). Nine patients had been treated with EP as induction therapy, while two patients had received high-dose cyclophosphamide, etoposide and cisplatin (HDCEP). Altogether, 18 patients had received previous intravenou
Los estilos APA, Harvard, Vancouver, ISO, etc.
Ofrecemos descuentos en todos los planes premium para autores cuyas obras están incluidas en selecciones literarias temáticas. ¡Contáctenos para obtener un código promocional único!

Pasar a la bibliografía